AlphaQuest LLC Has $635,000 Holdings in DexCom, Inc. (NASDAQ:DXCM)

AlphaQuest LLC lifted its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 428.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,165 shares of the medical device company's stock after acquiring an additional 6,621 shares during the quarter. AlphaQuest LLC's holdings in DexCom were worth $635,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Ellerson Group Inc. ADV boosted its holdings in shares of DexCom by 28.9% in the 4th quarter. Ellerson Group Inc. ADV now owns 70,035 shares of the medical device company's stock worth $5,447,000 after acquiring an additional 15,722 shares in the last quarter. Personal CFO Solutions LLC acquired a new position in shares of DexCom in the 4th quarter worth approximately $250,000. Dorsey & Whitney Trust CO LLC acquired a new position in shares of DexCom in the 4th quarter worth approximately $334,000. Marble Harbor Investment Counsel LLC boosted its holdings in shares of DexCom by 4.8% in the 4th quarter. Marble Harbor Investment Counsel LLC now owns 167,583 shares of the medical device company's stock worth $13,033,000 after acquiring an additional 7,674 shares in the last quarter. Finally, Larson Financial Group LLC boosted its holdings in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company's stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 45,083 shares of company stock worth $3,826,604 in the last three months. Insiders own 0.30% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Morgan Stanley upped their price objective on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Citigroup upped their price objective on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Finally, Canaccord Genuity Group upped their price objective on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $99.82.

Remove Ads

DexCom Price Performance

DXCM opened at $70.26 on Wednesday. The stock has a market cap of $27.46 billion, a P/E ratio of 49.13, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a fifty day simple moving average of $84.53 and a 200 day simple moving average of $76.98.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, research analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.